Our Team

John A. Sedor, Chairman & CEO


John A. Sedor, Chairman & CEO

John is a 30-year veteran of the pharmaceutical industry with a track record of creating value for shareholders at public and private companies.

Cangene: $220 million Sale of the Company
President, CEO, Board Member, Cangene Corporation (formerly TSX: CNJ)
2011 – 2014
Transformed Cangene from a biodefense developer/government contractor to a specialty pharmaceutical company
Divested non-core assets
Aligned manufacturing, marketing, and sales force across North America
Acquired Hemophelia assets from Ipsen
Acquired by Emergent BioSolutions in 2014 for $220 million, a 45% premium

Bentley: $375 million Sale of the Company
President, CEO, Bentley Pharmaceuticals (formerly NYSE: BNT) 2005-2008
Expanded nanotechnology programs,
lead the launch of more than 20 new product in the EU
Acquired by Teva Pharmaceutical Industries in 2008 for $375 million

CPEX: $75 million Sale of the Company
Chief Executive Officer, President and Director, CPEX Pharmaceuticals (formerly NASDAQ: CPEX) 2009-2011
Orchestrated the spin-off of CPEX from Bentley as part of the transaction with Teva
Led development/commercialization of patented drug delivery technology
Sold to Footstar in 2011 for $75 million

Sandoz (division of Novartis AG): Increased U.S. Sales to $1.2 Billion
President, Sandoz Inc. 2001–2005
Led efforts to more than double net sales growth and overall profitability

Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.

Currently, Mr. Sedor is a Board Member, Pernix Therapeutics (NASDAQ: PTX), a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products.  He also serves on the Board of Directors for Velico Medical Inc, a clinical-stage company developing product-candidates for blood transfusions safety.



Gary C. Floyd, Chief Operating Officer

Gary Floyd headshot

Gary C. Floyd, Chief Operating Officer

Gary is a seasoned pharmaceutical executive with over 40 years’ experience in the manufacture, sales and development of drugs and biologicals.

Armour Pharmaceutical Company

Plant Manager and Vice President of Operations of their 500,000 sq. ft. manufacturing plant that produced Small Volume and Large Volume sterile liquids, plasma proteins, oral drugs and inhalation products using form-fill-seal technology. In addition, he was Vice President of Marketing and Sales at Armour for North and South America.


Senior Vice President of Global Operations for Centeon, a combined Plasma Products company of Armour Pharmaceutical Company and Behringwerke, AG.

Aventis Behring

Senior Vice President of Worldwide Logistics

Eximias Pharmaceuticals/YM Biosciences   

In 2004, he joined Eximias Pharmaceuticals as head of Clinical Operations, Manufacturing and Quality Control.  Eximias later merged with YM Biosciences where he was Vice President of Operations and led manufacturing development, Quality Assurance and Assay Development.

Cangene Corporation

Chief Operating Officer of Cangene Corporation from 2012 to 2014 where he was responsible for regulatory compliance, quality assurance, manufacturing, analytical testing and development, project management and government contracting. He also served as the Chief Compliance Officer for the company.

Gary has a bachelor degree in Zoology and Chemistry from Olivet Nazarene University and has attended continuing education programs including Finance at University of Pennsylvania, Strategic Marketing at both Stanford and Harvard University and a Pharmacy program at the University of Tennessee.

Professional Associations

Member, American Association of Pharmaceutical Scientists



Barry R. Frankel, Chief Business Officer


Barry R. Frankel, Chief Business Officer

Barry has 40 years of experience in the life science industry, including investment research, strategic planning, company formation, licensing/mergers/acquisitions, and marketing.

Huron Consulting Group – Managing Director, Life Sciences

Assumed Life Science leadership role following successful sale of Frankel Group LLC to Huron Consulting Group. Engagements spanned the life science industry, and included repurposing/reformulation strategy for ANDA and 505(b)2 designations; global regenerative medicine and specialty dermatology strategies, including business definition, structure, LM&A targets and development strategy; and a range of new business formations and business model structures.

Frankel Group LLC – Founder & Managing Director

Founder of $20M, 50+ professional life science strategy consulting firm. Offices in New York NY, Cambridge, MA, Tel Aviv IS with global alliances. Engagements were across the industry, and included novel academic medical center/emerging R&D partnership strategy; restructuring, followed by board membership and ultimate sale of oncology therapeutics/diagnostics company; biologics company formation, funding, business strategy, joint venture strategy, and ultimate sale.

S.J. Weinstein Associates, INC – President and Partner

President of $30M billings healthcare marketing strategy and communications firm. Increased revenues over six fold during 10-year period; expanded firm product from core advertising to public relations, medical education, and strategic marketing consulting.

Pfizer Pharmaceuticals – Branded & Generic Anti-Infectives, Diagnostics Marketing; Strategic Planning

Marketing management of ethical and multi-source anti-infective product lines; launched third generation cephalosporin achieving leading share in category, and developed first wholesaler partnership marketing program for multi-source products. Marketing and new product development of microbiology instrument and reagent line; supervised National Accounts and Technical Support; relaunched instrument line and increased placements 250%. Business planning, licensing and acquisitions of diagnostic products business; divested imaging and clinical laboratory businesses via trade sales.

Citibank Investment Management Group – Senior Research Officer

Equity investment recommendations for $1B fund in life sciences; outperformance versus industry averages, 40% increase in fund allocation to 3X S&P 500 weighting.


Master of Business Administration, Finance, with Distinction, The Wharton School, University of Pennsylvania

Bachelor of Science, Engineering, Summa Cum Laude, College of Engineering, Rutgers University

Professional Associations

Board Member, Cireca Theranostics, BioAffinity, Nanocare Therapeutics

Advisor, Rutgers Center for Innovation and Emerging Technology (CIVET)

Chairman, Wainscott (New York) Community Advisory Council



Richard Lampe, Director of Regulatory Affairs & Quality Assurance

Richard Lampe has 30 years experience in the research and development functions, including development planning and management, US and EMEA regulatory and compliance, and start-up operational management.

AstraZeneca – Global Regulatory Affairs

CliniRx USA – Senior Director Regulatory Affairs for this CRO

Avarham Pharmaceuticals – Founding Member and Senior Director Regulatory Affairs

YM Biosciences – Senior Director Regulatory Affairs

New River Pharmaceuticals – Senior Director Regulatory Affairs